Second Sight Medical Products (NASDAQ: EYES) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it compare to its peers? We will compare Second Sight Medical Products to related businesses based on the strength of its risk, dividends, analyst recommendations, earnings, valuation, institutional ownership and profitability.
This table compares Second Sight Medical Products and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Second Sight Medical Products||-565.12%||-184.87%||-137.77%|
|Second Sight Medical Products Competitors||-101.23%||-92.70%||-30.32%|
This is a summary of recent recommendations and price targets for Second Sight Medical Products and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Second Sight Medical Products||0||0||1||0||3.00|
|Second Sight Medical Products Competitors||112||734||1028||10||2.50|
Second Sight Medical Products currently has a consensus target price of $5.00, suggesting a potential upside of 161.78%. As a group, “Medical Devices & Implants” companies have a potential upside of 39.86%. Given Second Sight Medical Products’ stronger consensus rating and higher probable upside, research analysts plainly believe Second Sight Medical Products is more favorable than its peers.
Institutional and Insider Ownership
12.8% of Second Sight Medical Products shares are owned by institutional investors. Comparatively, 54.8% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 34.7% of Second Sight Medical Products shares are owned by company insiders. Comparatively, 10.3% of shares of all “Medical Devices & Implants” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Risk and Volatility
Second Sight Medical Products has a beta of 3.67, meaning that its stock price is 267% more volatile than the S&P 500. Comparatively, Second Sight Medical Products’ peers have a beta of 0.47, meaning that their average stock price is 53% less volatile than the S&P 500.
Valuation & Earnings
This table compares Second Sight Medical Products and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Second Sight Medical Products||$3.98 million||-$33.17 million||-2.98|
|Second Sight Medical Products Competitors||$1.67 billion||$207.58 million||74.89|
Second Sight Medical Products’ peers have higher revenue and earnings than Second Sight Medical Products. Second Sight Medical Products is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Second Sight Medical Products peers beat Second Sight Medical Products on 7 of the 12 factors compared.
Second Sight Medical Products Company Profile
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.